advertisement
Abstract #8586 Published in IGR 5-1
Dorzolamide x apraclonidine in the prevention of the intraocular pressur spike after Nd:YAG laser posterior capsulotomy
Arieta CEL; Amaral MS; Matuda E; Crosta C; De Carvalho Moreira Filho D; Kara José NCurrent Eye Research 2002; 25: 237-241
OBJECTIVE: To evaluate the efficacy of dorzolamide compared to apraclonidine in the prevention of the intraocular pressure (IOP) spike after Nd:YAG laser posterior capsulotomu. METHODS: In a double-masked, prospective clinical trial, 217 eyes from 217 patients were randomly assigned to receive either dorzolamide two hours before and placebo one hour before Nd:YAG laser capsulotomy, or placebo two hours before and apraclonidine one hour before the procedure. Inclusion criteria were secondary cataracts with reduction in best-corrected visual acuity (BCVA < 20/40), absence of manifest or suspected glaucoma, and no known hypersensitivity to the study drugs. IOP was measured two hours and one hour before applying the laser, and one, two, and three hours, and seven days after. RESULTS: There were no statistically significant differences between the two groups regarding IOP at two hours and one hour before the procedure, or at one, two, and three hours, and seven days after laser treatment (p values: 0.077, 0.21, 0.085, 0.36, and 0.60, respectively). CONCLUSIONS: The results of this study suggest that dorzolamide is as safe and effective as apraclonidine in the prevention of IOP elevation after Nd:YAG laser posterior capsulotomy.
Dr. C.E.L. Arieta, Rua Joaquim Floriano, 72 cj 78, 04534-000, São Paulo, Brazil
Classification:
11.3.3 Apraclonidine, brimonidine (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
11.5.2 Topical (Part of: 11 Medical treatment > 11.5 Carbonic anhydrase inhibitors)
